Trevor Lissoos
Overview
Explore the profile of Trevor Lissoos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DHaens G, Dubinsky M, Kobayashi T, Irving P, Howaldt S, Pokrotnieks J, et al.
N Engl J Med
. 2023 Jun;
388(26):2444-2455.
PMID: 37379135
Background: Mirikizumab, a p19-directed antibody against interleukin-23, showed efficacy in the treatment of ulcerative colitis in a phase 2 trial. Methods: We conducted two phase 3, randomized, double-blind, placebo-controlled trials...
2.
Magro F, Pai R, Kobayashi T, Jairath V, Rieder F, Redondo I, et al.
J Crohns Colitis
. 2023 Apr;
17(9):1457-1470.
PMID: 37057827
Background And Aims: To evaluate the effect of mirikizumab, a p19-targeted anti-interleukin-23, on histological and/or endoscopic outcomes in moderately-to-severely active ulcerative colitis [UC]. Methods: Endoscopic remission [ER], histological improvement [HI],...
3.
Dubinsky M, Jairath V, Feagan B, Naegeli A, Tuttle J, Morris N, et al.
BMJ Open Gastroenterol
. 2023 Mar;
10(1).
PMID: 37001911
Objective: Mirikizumab, a monoclonal antibody targeting the interleukin-23 p19 subunit, was effective in a Phase 2 study (NCT02589665) of moderately-to-severely active ulcerative colitis (UC). We studied mirikizumab's impact on health-related...
4.
Kaplan J, Liu C, King E, Bass J, Patel A, Tung J, et al.
J Pediatr Gastroenterol Nutr
. 2023 Feb;
76(5):566-575.
PMID: 36804501
Background: Biologic medications are recommended for treatment of moderately-to-severely active Crohn disease (CD) or ulcerative colitis (UC) in children. However, many patients require sequential biologic treatment because of nonresponse or...
5.
Dubinsky M, Shan M, Delbecque L, Lissoos T, Hunter T, Harding G, et al.
J Patient Rep Outcomes
. 2022 Nov;
6(1):114.
PMID: 36334163
Background: The Urgency Numeric Rating Scale (NRS) was developed as a content-valid single-item patient-reported outcome measure to assess severity of bowel urgency. Here, we evaluated the psychometric properties of the...
6.
Chen G, Lissoos T, Dieyi C, Null K
Inflamm Bowel Dis
. 2020 Oct;
27(8):1177-1183.
PMID: 33043982
Background: Clinical indices to characterize the severity of inflammatory bowel disease (IBD) are widely used in clinical trials and real-world practice. However, there are few validated instruments for assessing IBD...
7.
Moran K, Null K, Huang Z, Lissoos T, Kane S
Adv Ther
. 2020 Mar;
37(4):1697-1700.
PMID: 32173794
No abstract available.
8.
Moran K, Null K, Huang Z, Lissoos T, Kane S
Adv Ther
. 2019 Aug;
36(9):2260-2272.
PMID: 31385283
Introduction: Patients' adherence to and persistence on treatment for inflammatory bowel disease (IBD) can vary, depending on type and distribution of disease and treatment modality. We aim to identify differences...
9.
Khan N, Vallarino C, Lissoos T, Darr U, Luo M
Inflamm Bowel Dis
. 2019 Apr;
26(3):462-468.
PMID: 30980714
Background: Inflammatory bowel disease (IBD) treatment in the elderly is challenging in part because of increased risk of infections. The aim of our study was to determine the absolute and...
10.
Ungaro R, Colombel J, Lissoos T, Peyrin-Biroulet L
Am J Gastroenterol
. 2019 Mar;
114(6):874-883.
PMID: 30908297
Objectives: In 2015, the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) program proposed shifting the therapeutic focus on ulcerative colitis (UC) toward altering the natural history of the disease...